| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c8ad230702e175c65a4cb382bc625436 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-146
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1658 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-14 |
| filingDate |
2020-12-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_76cf942674a8a8a9056844ca34eebc7c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b1df9927c4ddfc068e4a9cc2c1b22765
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9f5f62eca212f5c5ade48c256c129518 |
| publicationDate |
2022-08-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20220113964-A |
| titleOfInvention |
Joint amorphous forms of beta-lactoglobulin and drug substance |
| abstract |
The present invention relates to a drug substance and a protein, more particularly to co-amorphous forms of beta-lactoglobulin, wherein the purity of beta-lactoglobulin is at least 92% (w/w) of the total amount of protein contained in the co-amorphous form to be. The present invention also relates to compositions, such as pharmaceutical compositions comprising a cavity amorphous form. |
| priorityDate |
2019-12-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |